Michael H. Davidson insider trades: NewAmsterdam Pharma (NAMS) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Michael reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | NAMS | ↑ Buy | 10,000 | $22.65 | $227K | Direct | Sep 15, 2026 (1d) |
| Mar 2, 2026 | NAMS | ↓ Sell | 443,707 | $33.25 | $14.8M | Direct | Mar 2, 2026 (0d) |
| Feb 26, 2026 | NAMS | ↓ Sell | 306,293 | $34.53 | $10.6M | Direct | Feb 26, 2026 (0d) |
| Aug 20, 2024 | NAMS | ↑ Buy | 5,000 | $16.27 | $81K | Direct | Aug 22, 2024 (2d) |
| Jun 20, 2024 | NAMS | ↑ Buy | 5,000 | $17.26 | $86K | Direct | Jun 24, 2024 (4d) |
| Sep 9, 2020 | CLBS | ↑ Buy | 55,525 | $1.80 | $100K | Direct | Sep 10, 2020 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other NAMS insiders
Open-market trades in the last 12 months
About Michael H. Davidson's insider trades
Michael H. Davidson is Chief Executive Officer at NewAmsterdam Pharma (NAMS). Since Sep 9, 2020, Michael has reported 4 open-market purchases worth $494K and 2 sales worth $25.3M on SEC Form 4. In the last 12 months: 1 buy ($227K) and 2 sales ($25.3M).
Their filings also include grants and awards (15 filings), option exercises (4 filings), gifts (1 filing), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NAMS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.